Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: A randomized, double-blind, placebo-controlled trial

Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control by promoting GLP1-mediated glucose-dependent insulin secretion and suppression of glucagon. Sitagliptin and vildagliptin have been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).